



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not send a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

1

U. S. PATENT DOCUMENTS

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ Kind Code ⁵ (if known)				
AS/0		EP 0652009 A1	05/10/1995	Eli Lilly and Co.		
AS/0		WO 00/77030 A1	12/21/2000	Elan Pharmaceuticals		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	10/840,037
				Filing Date	May 6, 2004
				First Named Inventor	Klaus Fuchs
				Art Unit	1614
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	1/1497

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
<i>SA</i>		ROY K. HOM ET AL; Design and Synthesis of Statine-Based Cell-Permeable Peptidomimetic Inhibitors of Human beta-secretase; Journal of Medicinal Chemistry (2003) Vol. 46 Pages 1799-1802; American Chemical Society				
		JAY S. TUNG ET AL; Design of Substrate-Based Inhibitors of Human beta-secretase; Journal of Medicinal Chemistry (2002) Vol. 45 pages 259-262; American Chemical Society				
		KWAN Y. HUI ET AL; Design of Rat Renin Inhibitory Peptides; Journal of Medicinal Chemistry (1988) Vol 31 pages 1679-1686; American Chemical Society				
		DINO NISATO ET AL; Renin Inhibitors. Free-Wilson and Correlation Analysis of the Inhibitory Potency of a Series of Pepstatin Analogues on Plasma Renin; Journal of Medicinal Chemistry (1987) VOL. 30 PAGES 2287-2291; American Chemical Society				
		REMY GUEGAN ET AL; Pepstatin Analogues as Novel Renin Inhibitors; Journal of Medicinal Chemistry (1986) Vol. 29 pages 1152-1159; American Chemical Society				
<i>AT</i>		PETZ KUZMIC ET AL; Long Range Electrostatic Effects in Pepsin Catalysis; Tetrahedron (1991) Vol. 47 No. 14-15 pages 2519-2534; Pergamon Press				
<i>TS</i>		Copy of International Search Report Reference No. PCT/EP2004/005007				

Examiner Signature	<i>SA</i>	Date Considered	8/12/05
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.